Related Experiment Video
Updated: Oct 26, 2025
Assays for the Identification of Novel Antivirals against Bluetongue Virus
Published on: October 11, 2013
Identification of novel topoisomerase II alpha inhibitors by virtual screening, molecular docking, and bioassay
Che Yu1, Jiabao Hu2, Walter Luyten3
1Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Abstract:
Breast cancer is one of the most common tumors, and its treatment still leaves room for improvement. Topoisomerase II alpha is a potential target for the treatment of human diseases such as breast cancer. In this article, we attempted to discover a novel anticancer drug. We have used the topoisomerase II alpha protein-Homo sapiens (Human) to hierarchically screen the Maybridge database. Based on their docking score, the top hit compounds have been assayed for inhibition in a topoisomerase II pBR322 DNA relaxation assay in vitro. Candidate compound 6 (CP6) was found to have the best inhibitory effect for topoisomerase II among the 20 tested compounds. In addition, CP6 had potent cytotoxicity against eight tested tumor cell lines. At the same time, CP6 was shown to have potential anti-multidrug resistance capabilities. This study identifies CP6, which can contribute to the development of new topoisomerase II inhibitors as anticancer agents.
Insights
Researchers identified a novel anticancer drug candidate, CP6, which shows potent inhibition against topoisomerase II and cytotoxicity against multiple tumor cell lines. CP6 also demonstrates potential in overcoming multidrug resistance in cancer treatment.
Area of Science:
- Biochemistry
- Oncology
- Drug Discovery
Background:
- Breast cancer remains a significant global health challenge with ongoing needs for improved therapeutic strategies.
- Topoisomerase II alpha (TOP2A) is a validated molecular target in cancer therapy, particularly for breast cancer.
- Developing novel inhibitors targeting TOP2A is crucial for advancing breast cancer treatment.
Purpose of the Study:
- To discover and characterize novel small molecules that inhibit human topoisomerase II alpha (TOP2A).
- To identify potential anticancer agents with improved efficacy and mechanisms of action.
- To explore the anti-multidrug resistance capabilities of newly identified compounds.
Main Methods:
- Hierarchical screening of the Maybridge compound database against human TOP2A.
- In vitro assessment of TOP2A inhibition using a DNA relaxation assay.
- Evaluation of compound cytotoxicity against a panel of eight human tumor cell lines.
- Assay for anti-multidrug resistance properties.
Main Results:
- Candidate compound 6 (CP6) emerged as the most potent TOP2A inhibitor among 20 tested compounds based on docking scores and in vitro assays.
- CP6 exhibited significant cytotoxicity across eight diverse tumor cell lines.
- CP6 demonstrated promising potential in overcoming multidrug resistance mechanisms.
Conclusions:
- CP6 is identified as a promising novel anticancer agent with dual action as a TOP2A inhibitor and a potential modulator of multidrug resistance.
- This discovery supports the development of CP6 as a new therapeutic option for breast cancer and potentially other malignancies.
- Further investigation into CP6's mechanism of action and in vivo efficacy is warranted.
More Related Videos
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
10:25Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology
Published on: November 22, 2024
